Trial Profile
Influence of Cytochrome P2B6 on Efavirenz Dose in HIV-infected Thai Patients in a Prospective Randomized Controlled Trial: a Proof-of-concept Study
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Efavirenz (Primary)
- Indications HIV-1 infections
- Focus Pharmacodynamics; Proof of concept
- 03 Aug 2015 Minimum age limit changed from 15 years to 18 years.
- 24 Apr 2015 New trial record